Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-02-15

FDA Approved: TEPMETKO — Supplemental Application (EMD Serono, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Tepmetko (tepotinib hydrochloride) from EMD Serono, Inc., expanding its approved indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Tepmetko (tepotinib)

Snippet

SUPPL AP for TEPMETKO (TEPOTINIB HYDROCHLORIDE)